A new company brings together two technologies: lab-grown insulin-producing cells and an implantable pouch designed to help those cells survive and function inside the body. Sernova makes the pouch, Seraxis grows the cells – together they are BetaNova hopes that bringing these two technologies together could move us closer to a functional cure for type 1 diabetes.
So what does this merger really mean? What makes these cells different? And could this approach eventually work without immunosuppressive drugs and actually be available to millions of people with type 1?
I'm talking with the CEOs of the companies that are merging: Jonathan Rigby – who lives with type 1 - and Will Rust about the science, the challenges, and why they believe this combination could be a game changer.
Podden och tillhörande omslagsbild på den här sidan tillhör
Stacey Simms. Innehållet i podden är skapat av Stacey Simms och inte av,
eller tillsammans med, Poddtoppen.